Livazo, 2 mg 28 pcs.

Pitavastatin competitively inhibits HMG-CoA reductase, limiting the rate of action of the enzyme in cholesterol biosynthesis, inhibits the synthesis of cholesterol (Chs) in the liver. As a consequence, LDL receptor expression in the liver is increased, contributing to the uptake of circulating LDL in the blood, lowering total Chs and LDL cholesterol (Chs-LDL) in the blood. Its persistent inhibition of hepatic Chs synthesis reduces LDL secretion into the blood, lowering plasma triglyceride levels.

Indications

Primary hypercholesterolemia, including heterozygous familial hypercholesterolemia (Fredrickson type IIa hyperlipidemia) or mixed hypercholesterolemia (Fredrickson type IIb hyperlipidemia), hypertriglyceridemia (Fredrickson type IV hyperlipidemia) as an adjunct to diet, when diet and other non-drug treatments (eg, exercise, weight loss) are insufficient.

Pharmacological effect

Pitavastatin competitively inhibits HMG-CoA reductase, limiting the rate of action of the enzyme in cholesterol biosynthesis, and inhibits the synthesis of cholesterol (C) in the liver. As a result, the expression of LDL receptors in the liver increases, promoting the uptake of circulating LDL in the blood, reducing total cholesterol and LDL cholesterol (LDL-C) in the blood. Its persistent inhibition of hepatic cholesterol synthesis reduces the secretion of LDL into the blood, reducing plasma triglyceride levels.

Special instructions

Effect on muscles

Active ingredient

Pitavastatin

Composition

Active substance:

Contraindications

Severe liver failure (more than 9 points on the Child-Pugh scale) or class C according to the Child-Pugh classification, liver disease and active phase, including a persistent increase in the activity of liver transaminases in the blood serum (more than 3 times compared to ULN); myopathy; simultaneous use of cyclosporine; pregnancy, breastfeeding, lack of adequate methods of contraception in women of childbearing age; age under 18 years (efficacy and safety have not been established); hypersensitivity to pitavastatin, auxiliary components of the drug and other HMG-CoA reductase inhibitors (statins).

Side Effects

Frequency is defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000), very rare (<1/10,000) and unknown.

Interaction

Cyclosporine: with simultaneous use of a single dose of cyclosporine with Livazo at steady state, an increase in the AUC of pitavastatin by 4.6 times was observed. Livazo is contraindicated in patients receiving treatment with cyclosporine.

Overdose

In case of overdose, symptoms of adverse reactions may increase.

Storage conditions

The drug should be stored in its original packaging, protected from light, out of the reach of children, at a temperature not exceeding 25°C.

Shelf life

4 years.

Manufacturer

Pierre Fabre Medicine Production, France